Form4insider filings, from the source

SEC Form 4 · accession 0000899243-19-002666

Global Blood Therapeutics, Inc. · GBT

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner
Ted W Love
Officer — See Remarks · Director
Period of report
Feb 1, 2019
Accepted (ET)
Feb 5, 2019 · 5:53 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001629137

Table I — non-derivative securities

SecurityDateCodeSharesPriceA/DOwned afterD/INature of ownership
Common StockF1Feb 1, 2019M21,813—A1,150,788D
Common StockF2Feb 1, 2019F7,814$48.44D1,142,974D
Common Stockholding———2,500IBy Daughter
Common Stockholding———2,500IBy Daughter

Table II — derivative securities

SecurityConv. / exercise priceDateCodeSharesA/DExercisableExpiresUnderlyingUnderlying sharesOwned afterD/I
Stock Option (Right to Buy)F3$48.44Feb 1, 2019A145,000A—Jan 31, 2029Common Stock145,000145,000D
Restricted Stock UnitsF1,F4—Feb 1, 2019A90,000A——Common Stock90,00090,000D
Restricted Stock UnitsF1,F5—Feb 1, 2019M12,063D——Common Stock12,06348,250D
Restricted Stock UnitsF1,F6—Feb 1, 2019M9,750D——Common Stock9,75058,500D

Explanation of responses

Remarks

Chief Executive Officer and President